文献速递胃肠外科

MGMT蛋白表达与II/III期胃癌术后预后及辅助化疗获益的关联

Association of O6-Methylguanine-DNA Methyltransferase Protein Expression With Postoperative Prognosis and Adjuvant Chemotherapeutic Benefits Among Patients With Stage II or III Gastric Cancer.
PubMed 文献 · JAMA Surg · 2017-11-15

该研究纳入445例接受根治性胃切除术的可切除胃癌患者,随机分为发现集(n=200)和验证集(n=245),评估MGMT蛋白免疫反应性与预后的关系。

要点

  • MGMT阳性表达是II/III期胃癌术后独立良好预后因素。
  • II期胃癌中MGMT阳性者氟尿嘧啶辅助化疗获益更显著。
  • 将MGMT表达纳入TNM分期可能提高预后准确性。

核心结论

  • 胃癌中MGMT阳性表达被确定为独立且有利的预后因素。
  • 将MGMT表达纳入现行TNM分期系统可能提高预后准确性。
  • 这些发现需在随机临床试验框架内结合基因组DNA测序研究进一步确认。

研究设计与样本

  • 研究招募了2007年8月1日至2008年12月30日在复旦大学附属中山医院接受根治性胃切除术的445例连续可切除胃癌患者。
  • 患者被随机分为发现数据集(n=200)和验证数据集(n=245)。
  • 发现组随访时间范围为2至76个月,验证组为2至79个月。
  • 由两名对临床病理数据不知情的病理学家在光镜下审查癌细胞中MGMT的免疫反应性。

主要发现

  • 多变量分析确定MGMT表达和TNM分期为总生存的两个独立预后因素。

临床怎么用

  • 对于II/III期胃癌术后患者,可考虑检测MGMT蛋白表达以辅助预后评估。
  • 在II期胃癌中,MGMT阳性表达可能提示从氟尿嘧啶为基础的辅助化疗中获益更多。
  • 将MGMT表达信息纳入TNM分期系统可能改善预后判断准确性。

局限性

  • 研究为回顾性设计,发现需在随机临床试验中确认。
  • 需结合基因组DNA测序研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Loss of O6-methylguanine-DNA methyltransferase (MGMT) protein expression has been reported in several malignant tumors and predicts dismal survival outcomes. In gastric cancer, existing studies on this topic are limited and the association between MGMT and fluorouracil-based adjuvant chemotherapy remains obscure. OBJECTIVE: To investigate the postoperative prognostic significance of MGMT in patients with resectable gastric cancer and its responsiveness to fluorouracil-based adjuvant chemotherapy. DESIGN, SETTING, AND PARTICIPANTS: This study recruited 445 consecutive patients with resectable gastric cancer who underwent radical gastrectomy between August 1, 2007, and December 30, 2008, at Zhongshan Hospital at Fudan University in Shanghai, China. Patients were randomly divided into a discovery data set (n = 200) and a validation data set (n = 245), and the range of follow-up time was from 2 to 76 months for the discovery group and 2 to 79 months for the validation group. The immunoreactivity for MGMT in cancer cells was reviewed under a light microscope by 2 pathologists who were blinded to the clinicopathological data. The association of MGMT expression with clinicopathological characteristics and measures and prognosis was inspected. Data and specimens were collected from patients from the date of surgery to April 25, 2014. Data analysis took place from May 9, 2016, to July 15, 2016. MAIN OUTCOMES AND MEASURES: Estimates of overall survival on the basis of MGMT expression and hazard ratio (HR) for estimates of overall mortality risk. RESULTS: Of the 445 patients included in the study, 315 (70.8%) were men, and the mean (SD) age of all patients was 60 (12) years. Positive expression of MGMT indicated better overall survival for patients with stage II or III gastric cancer in both the discovery data set (HR, 0.52; 95% CI, 0.32-0.84; P = .003) and the validation data set (HR, 0.63; 95% CI, 0.43-0.93; P = .01). Multivariate analysis identified MGMT expression and TNM stage as 2 independent prognostic factors for overall survival. In stage II disease, the benefit from fluorouracil-based adjuvant chemotherapy was superior among MGMT-positive patients (HR, 0.35; 95% CI, 0.13-0.95; P = .007 for interaction) compared with MGMT-negative patients. CONCLUSIONS AND RELEVANCE: Positive expression of MGMT in gastric cancer was identified as an independent, favorable prognostic factor. Incorporating MGMT expression into the current TNM staging system could lead to better prognostic accuracy. These findings should be confirmed within the framework of randomized clinical trials associated with genomic DNA sequencing studies.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Cao Y, Liu H, Li H, et al. Association of O6-Methylguanine-DNA Methyltransferase Protein Expression With Postoperative Prognosis and Adjuvant Chemotherapeutic Benefits Among Patients With Stage II or III Gastric Cancer. JAMA Surg. 2017. PMID: 28903131. doi:10.1001/jamasurg.2017.3120

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。